The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,115,185 in first-year total cost, median $1,115,185.
Most frequent study sections
- Special Emphasis Panel[ZNS1 SRB-G (81)]1
Most frequent institutions
- AZEVAN PHARMACEUTICALS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Tolerability of SRX246 in Huntington's Disease Patients1U44NS090616-01A1 | BROWNSTEIN, MICHAEL JCOFFEY, CHRISTOPHER S.CUDKOWICZ, MERIT EHERSCH, STEVEN M | AZEVAN PHARMACEUTICALS, INC., PA | $1,115,185 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.